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ABSTRACT
Objective: To characterize nonpsychiatric prescription patterns of antidepressants according to drug labels and
evidence assessments (on-label, evidence-based, and off-label) using structured outpatient electronic health record (EHR) data.
Methods: A retrospective analysis was conducted using deidentified EHR data from an outpatient practice at a
New York City-based academic medical center. Structured “medication–diagnosis” pairs for antidepressants
from 35 325 patients between January 2010 and December 2015 were compared to the latest drug product
labels and evidence assessments.
Results: Of 140 929 antidepressant prescriptions prescribed by primary care providers (PCPs) and nonpsychiatry specialists, 69% were characterized as “on-label/evidence-based uses.” Depression diagnoses were associated with 67 233 (48%) prescriptions in this study, while pain diagnoses were slightly less common (35%). Manual chart review of “off-label use” prescriptions revealed that on-label/evidence-based diagnoses of depression
(39%), anxiety (25%), insomnia (13%), mood disorders (7%), and neuropathic pain (5%) were frequently cited as
prescription indication despite lacking ICD-9/10 documentation.
Conclusions: The results indicate that antidepressants may be prescribed for off-label uses, by PCPs and nonpsychiatry specialists, less frequently than believed. This study also points to the fact that there are a number of
off-label uses that are efficacious and widely accepted by expert clinical opinion but have not been included in
drug compendia. Despite the fact that diagnosis codes in the outpatient setting are notoriously inaccurate, our
approach demonstrates that the correct codes are often documented in a patient’s recent diagnosis history. Examining both structured and unstructured data will help to further validate findings. Routinely collected clinical
data in EHRs can serve as an important resource for future studies in investigating prescribing behaviors in outpatient clinics.
Key words: antidepressants, prescription patterns, EHR, outpatient
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INTRODUCTION

METHODS
Study design
This retrospective study was conducted using outpatient EHR data
(Epic SystemsV) at a large New York City-based academic medical
center. The EHR data repository was queried to retrieve demographics, encounter, diagnosis, and associated medication data for
outpatients who had received antidepressants.21 As of July 2016,
there were 123 702 unique patients who had been prescribed a total
of 401 734 unique prescriptions of antidepressant medications.
This study, however, included only those antidepressant
prescriptions actively written for individuals aged 18 between
R

Prescription classification
For the purposes of this study, prescriptions were then classified as
“on-label” if an associated diagnosis matched those provided in the
FDA list of approved indications, or “evidence-based” for diagnoses
in which evidence favors efficacy as of August 2016. We applied
methods previously reported,20,23 in which product label information, class of recommendation, and the strength of scientific evidence or clinical effectiveness assessments were distinguished by the
DrugDex system (Truven Health Analytics Micromedex Solutions,
Greenwood Village, CO, USA).24 DrugDex is considered to be an
authoritative compendium, which is used by the Centers for Medicare and Medicaid Services (CMS) to determine coverage for offlabel uses of medications, and has also been used for research in
multiple prior studies.23,25–32 Within the compendium, benefit classes range from I (strong, benefit o risk) to III (No benefit or benefit
 risk), and level of evidence ranges from Category A to C-EO.
Only those medication–indication pairs in which the class of recommendation is listed as I, IIa (moderate, benefit  risk), or IIb (weak,
benefit  risk), and evidence Category A (high quality evidence
from >1 RCT) or B (moderate evidence from  1 RCT or welldesigned nonrandomized study, observational study, etc.) were considered as medically accepted and rigorous enough for this study.
The list of antidepressant classes found in the dataset and their onlabel/evidence-based uses are included in Table 1. The full list of
each individual antidepressant medication and their on-label/
evidence-based uses can be found in Supplementary Table S1.
Finally, all prescriptions associated with diagnoses that were not
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In the United States (US), treatment for depression is increasingly occurring outside of traditional contexts and predominantly in the primary care setting.1–4 The collaborative and integrative care
movement embraces the expansion of treatment across broader
medical populations but also emphasizes a team-based approach, involving psychiatrists as consultants—thereby improving care and
widening of the arc of nonpsychiatrists who prescribe antidepressants.3,4 Despite its promise, collaborative care has yet to become
standard practice—thus understanding the patterns of medication
prescribing by primary care providers (PCPs) and nonpsychiatric
specialists is important because it remains unclear as to how antidepressants are being prescribed in this setting.
The prescribing patterns of nonpsychiatrists are of particular importance because the prevalence of antidepressant medication use is
rising in the US.5–7 This increase is partly driven by a greater number
of medications on the market,8 improved public acceptance of psychiatric drugs,9 and a broadening of the clinical indications. According to the Centers for Disease Control and Prevention, use of
antidepressants has increased nearly 5-fold in the US since the
1980s, and roughly 12% of the adult population are now taking
these medications.10,11 Antidepressants are primarily designed to
treat depression and anxiety, but they are commonly prescribed for
related problems such as chronic pain,12 neuropathies,13,14
insomnia,15,16 and eating disorders.17 Prescriptions for indications
other than those approved by the US Food and Drug Administration
(FDA) are considered to be “off-label,” and have been estimated to
occur at nearly 30% or higher for antidepressant medications.18–20
However, the drug label is not always a comprehensive indicator of
a medication’s use. In fact, drug labels and evidence assessments are
frequently determined by pharmaceutical marketing strategies,
incentives for research and development, and the cost of randomized
controlled trials (RCTs).
Despite an increase in antidepressant prescriptions, there is limited knowledge on trends in prescribing by PCPs and nonpsychiatric
specialists.6,20 For instance, the risk/benefit ratios of most off-label
uses are variable, thus there is added benefit to understanding
“real-world” prescription patterns with respect to drug labels and
evidence assessments. Electronic health records (EHRs) routinely
collect data on prescription patterns across all care settings including
outpatient and inpatient practices, and emergency departments, and
may provide further insight into clinical use of medications. Additionally, EHRs provide a platform for longitudinal data collection
covering a wide range of phenotypic expressions via both structured
data and unstructured clinical text. Therefore, the primary goal of
our study is to characterize nonpsychiatric outpatient prescriptions
of antidepressants using structured diagnosis data from EHRs.

January 1, 2010 and December 31, 2015—to capture more than 5
full years of data during a period in which the EHR Computerized
Provider Order Entry (CPOE) use was predominant. We queried
prescriptions issued at the institution’s outpatient practices (stored
as a structured data element in the EHR data repository) and not
those documented as historical medications because of potential recall biases and inaccurate association of indications for each prescription. Antidepressant medications were identified using
national drug codes (NDC) located in the Healthcare Effectiveness
Data and Information Set (HEDIS) 2016 final NDC lists.22 The
HEDIS lists are provided by the National Committee for Quality
Assurance (NCQA) and represent unique codes for distinct combinations of drug ingredients, strength, and route. Structured diagnoses were coded according to the International Classification of
Diseases, Ninth and Tenth Revisions, Clinical Modification (ICD9-CM/ICD-10-CM). Both ICD-9 and ICD-10 codes are available
for all diagnoses in the EHR system due to extensive code mapping
completed at the institution during the code transition period surrounding October 2015. However, given that the transition occurred at the end of the study period, our syntax searched for
relevant ICD-9 codes prior to ICD-10. We excluded all prescriptions that had been issued by physicians, certified nurse practitioners and other healthcare providers with prescribing privileges
from the Department of Psychiatry, choosing instead to focus only
on PCP and nonpsychiatric specialty prescribing. Lastly, to account
for recent medical history, each prescription was matched to all
structured diagnoses made for the corresponding patient during
the previous 5 years (including data between 2005 and 2015). After applying our inclusion/exclusion criteria, we were left with
35 325 unique patients and 140 929 prescriptions between 2010
and 2015 (Figure 1).
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matched to drug labels or evidence assessments, were considered to
be off-label use.
In order to determine the effect that medical history played on the
classification of prescriptions, we then examined trends in on-label/evidence-based versus off-label use over periods of up to 5 years prior to
each prescription date (Figure 2A and B). The 5-year time frame was
selected because it represents a period of recent medical history in
which an individual likely still suffers from the chronic ailments that
are traditionally associated with antidepressant medications. In addition, past medical history is not always recaptured via diagnosis codes

in subsequent clinical encounters. Five years is also close to the upper
limit of mean data available in the outpatient EHRs. Medication–
diagnosis pairs and on-label/evidence-based classifications using the 5year time frame are characterized in Table 2.
For prescriptions classified as off-label use, only those diagnoses
that were made during the most recent clinical encounter were included in the analysis. This was done based on the findings that no
diagnoses during the selected medical history window could be
matched to product labels or evidence assessments, yet a structured
diagnosis was required for the analysis.
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Figure 1. Prescription eligibility CONSORT diagram.
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Table 1. DrugDex list of antidepressant classes by on-label and
evidence-based uses
On-label use

Evidence-based use

SSRI

Abnormal vasomotor
function—menopause
Bulimia
Depression

Alcoholism

Generalized anxiety disorder
Obsessive–compulsive
disorder
Panic disorders
Post-traumatic stress
disorder
Premenstrual disorders
Social phobia

SNRIs

Chronic pain (musculoskeletal)
Depression
Diabetic neuropathy—
pain
Fibromyalgia
Generalized anxiety disorder
Panic disorders
Social phobia

Therapeutic
class

On-label use

Binge-eating syndrome
Bipolar disorder, depressed phase; adjunct
Body dysmorphic disorder
Cancer—depression
Cancer pain
Cerebrovascular accident—depression
Coronary arteriosclerosis—depression
Depression
Depression—diabetes
mellitus
Depression—myocardial
infarction; post
Drug-induced depressive
state
Dysthymia
Eating disorder
Fibromyalgia
Generalized anxiety disorder
Hot sweats
Mixed anxiety and depressive disorder
Night eating syndrome
Obsessive–compulsive
disorder
Panic disorder
Postmenopausal flushing
Post-traumatic stress disorder
Premature ejaculation
Premenstrual dysphoric
disorder
Raynaud’s phenomenon
Severe depression with
psychotic features; adjunct
Social phobia
Vasovagal syncope
Attention-deficit/
hyperactivity disorder
Binging–eating disorder
Bipolar disorder, depressed phase
Cerebrovascular accident—depression
Depression—perimenopausal disorder
Diabetic neuropathy
Dysthymia
Hot sweats, breast cancer-related
Menopausal flushing
Migraine
(continued)

Tricyclic

Alcoholism
Anxiety
Depression
Endogenous depression
Insomnia
Nocturnal enuresis (pediatric only)
Obsessive–compulsive
disorder
Pruritus
Psychotic depressive
disorders
Severe major depression
with psychotic features

Tetracyclic

Bipolar disorder
Depression
Dysthymia
Mixed anxiety and depressive disorder

Phenylpiperazine
Misc.

Depression
Depression
Depression, associated
with seasonal affective disorder; prophylaxis
Smoking cessation
Bipolar disorder

Others

Evidence-based use

Obsessive–compulsive
disorder
Pain, chemotherapy-induced—peripheral
nerve disease
Post-traumatic stress disorder
Premenstrual dysphoric
disorder
Recurrent major depressive episodes; prophylaxis
Tension-type headache;
prophylaxis
Urinary incontinence
ADHD
Binging
Cataplexy
Delusional disorder
Depression
Diabetic neuropathy
Disorder of ejaculation
(sex dysfunction)
Fibromyalgia
Headache
Irritable bowel syndrome

Neurogenic bladder
Nocturnal enuresis
Obsessive–compulsive
disorder; intravenous
therapy
Pain
Pain, chronic
Panic disorder
Postherpetic neuralgia
Smoking cessation assistance
Subjective tinnitus
Urinary incontinence
Urticaria
Anxiety
Cancer, symptomatology
Dysthymia
Obsessive–compulsive
disorder
Pain
Panic disorder
SSRI adverse reaction—
sexual dysfunction
Insomnia
Bipolar disorder
Sexual dysfunction due to
substance, SSRI

Agoraphobia
(continued)
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Therapeutic
class
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Table 1. continued
Therapeutic
class

Evidence-based use

Depression
Depression, atypical,
nonendogenous, or
neurotic
Mixed anxiety and depressive disorder
Schizophrenia

Bulimia nervosa
Social phobia

Notes: Selective Serotonin Reuptake Inhibitor (SSRI) includes citalopram,
escitalopram, fluoxetine, fluvoxamine, paroxetine, and sertraline. SerotoninNorepinephrine Reuptake Inhibitor (SNRI) includes desvenlafaxine, duloxetine, levomilnacipran, and venlafaxine. Tricyclic antidepressants include amitriptyline, amoxapine, clomipramine, desipramine, doxepin, imipramine,
nortriptyline, and protriptyline. Tetracyclic antidepressants include maprotiline and mirtazapine. Phenylpiperazine includes trazodone and nefazodone.
Miscellaneous antidepressants include bupropion, vilazodone, and vortioxetine. Others include monoamine oxidase inhibitors (MAOIs): phenelzine and
tranylcypromine; and psychotherapeutic combinations: fluoxetine-olanzapine, amitriptyline-chlordiazepine and amitriptyline-perphenazine.

Assessment and validation of indication identification
In order to assess the accuracy of our methodology, we then performed a sensitivity analysis via chart review on 1% of the patients
that had received a prescription for an off-label use (npatients ¼
259).33 During this review, we randomly sampled patients and their
prescriptions, then compared the encounter diagnoses that were
listed in our dataset to the diagnoses that were specifically linked to
each prescription within the EHR system. If a patient received two
different antidepressant prescriptions in the same encounter, both
were recorded (nprescriptions ¼270). In addition, we reviewed clinical
notes to determine the physician-documented reason for ordering
the antidepressant. A sample of the results are displayed in Table 4.
As an added validation step, a chart review was performed on 1%
of the patients (npatients ¼ 190) that had received an on-label/
evidence-based use prescription, comparing the earliest approved
structured diagnosis to the physician-documented indication within
the clinical text.
All data management and analyses were performed using SAS
software version 9.4 (SAS Institute). This study was reviewed and
approved by the Institutional Review Board (No. 1510016639).

RESULTS
Study cohort characteristics
On average, we had 4.1 (65.8) unique antidepressant prescriptions
and 3.0 (62.7) years of diagnosis data per patient. The mean age of
the study population was 56.7 (616.4) years. There were also twice
as many females (67%) in the population as males.

Examination of treatment indications and prescriptions
patterns

Figure 2. (A and B) Prescription classification adjusted by no. of days of medical history examined, 1 year (A) and 5 year (B).

We examined the distribution of prescriptions within the context
of the medical specialty of the prescriber. For the clinical specialties
in which the greatest number of off-label use prescriptions were issued, we tabulated major characteristics of the prescriptions. Such
characteristics included prominent diagnosis classes, number of prescriptions on which the classes occur, the most common diagnoses
within each class, and most frequently prescribed antidepressant

Frequencies of prescriptions stratified by treatment indication and
on-label/evidence-based use classification are provided in Table 2.
Using our matching method, the most commonly appearing diagnoses across all prescriptions were depressive disorders (48%), pain
(35%), anxiety disorders (23%), symptoms (eg chronic fatigue and
malaise) (17%), digestive system disorders (15%), insomnia (13%),
weight problems (12%), and headache or migraine (11%). All prescriptions which included a diagnosis of depression in the previous 5
years were written for on-label/evidence-based uses, while prescriptions with histories of insomnia or anxiety disorders were supported
by on-label/evidence-based uses 93% and 87% of the time, respectively.
Prescriptions classified as off-label uses were most frequently associated with diagnoses of Parkinson’s disease (32%), headache/migraine (25%), bipolar disorder (20%), fibromyalgia (17%), weight
problems, and pain (16%).

Characterization of off-label use prescription patterns
by medical specialty
Prescriptions classified as off-label use were stratified by medical
specialty and further analyzed in an attempt to further investigate
the clinical reason for the prescription order. Table 3 also shows
that specialty prescribing often includes diagnoses of chronic and/or
debilitating conditions that have been associated with depression.
Anxiety and pain seem to also be commonly diagnosed. Internal
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drug classes (Table 3). Diagnosis classes and specific diagnoses were
chosen based on their frequency within the specialty, severity, and
potential relationship with depression.
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Table 2. Treatment indication diagnoses and prescribing patterns for antidepressant medications, 2010–2015
Prescription diagnosesa

For on-label use (%)c

67 233 (47.7)
48 680 (34.5)
32 890 (23.3)
23 240 (16.5)
21 596 (15.3)
18 377 (13.0)
16 612 (11.8)
15 109 (10.7)
14 604 (10.4)
11 471 (8.1)
10 456 (7.4)
8593 (6.1)
7702 (5.5)
5174 (3.7)
4807 (3.4)
4027 (2.9)
3554 (2.5)
3266 (2.3)
2733 (1.9)
2580 (1.8)
2550 (1.8)
1782 (1.3)
1732 (1.2)
1395 (1.0)
1189 (0.8)
1186 (0.8)
950 (0.7)
849 (0.6)
187 (0.1)
117 845 (83.6)

For off-label use (%)

n ¼ 78 468 (55.7)

Where evidence
favors efficacy (%)d
n ¼ 18 613 (13.2)

65 475 (97.4)
33 591 (69.0)
23 490 (71.4)
16 968 (73.0)
16 051 (74.3)
12 610 (68.6)
12 342 (74.3)
8043 (53.2)
11 248 (77.0)
8404 (73.3)
7797 (74.6)
7504 (87.3)
4655 (60.4)
3658 (70.7)
4313 (89.7)
2275 (56.5)
2957 (83.2)
2538 (77.7)
2118 (77.5)
1243 (48.2)
2230 (87.5)
1491 (83.7)
1033 (59.6)
898 (64.4)
992 (83.4)
940 (79.3)
805 (84.7)
620 (73.0)
178 (95.2)
69 772 (59.2)

1758 (2.6)
7233 (14.9)
5049 (15.4)
3506 (15.1)
2855 (13.2)
4609 (25.1)
1565 (9.4)
3354 (22.2)
1876 (12.8)
1932 (16.8)
1301 (12.4)
791 (9.2)
1716 (22.3)
822 (15.9)
347 (7.2)
947 (23.5)
456 (12.8)
399 (12.2)
572 (20.9)
1017 (39.4)
202 (7.9)
118 (6.6)
139 (8.0)
317 (22.7)
147 (12.4)
210 (17.7)
131 (13.8)
99 (11.7)
2 (1.1)
14 930 (12.7)

0 (0)
7856 (16.1)
4351 (13.2)
2766 (11.9)
2690 (12.5)
1158 (6.3)
2705 (16.3)
3712 (24.6)
1480 (10.1)
1135 (9.9)
1358 (13.0)
298 (3.5)
1331 (17.3)
694 (13.4)
147 (3.1)
805 (20.0)
141 (4.0)
329 (10.1)
43 (1.6)
320 (12.4)
118 (4.6)
173 (9.7)
560 (32.3)
180 (12.9)
50 (4.2)
36 (3.0)
14 (1.5)
130 (15.3)
7 (3.7)
33 143 (28.1)

n ¼ 43 848 (31.1)

Note: All variables are represented as counts (percentage).
a
Five-year diagnosis history was accounted for, and 68% of all antidepressant prescriptions had multiple treatment indications and thus were assigned to more
than one category. Therefore, the sum of prescriptions across the individual treatment indication categories exceeds the total number of prescriptions (first row).
b
Percentages calculated using the total number of antidepressant prescriptions for any indication (N ¼ 140 929) as the denominator.
c
Number of prescriptions that were considered on-label for the specified treatment indication, according to the US Food and Drug Administration (FDA).
d
This column reflects the number of antidepressant prescriptions that were written in which the evidence favors efficacy for treatment of the associated diagnosis, as noted by the DrugDex System.

medicine specialists predominantly prescribed selective-serotonin reuptake inhibitors (SSRI’s) and diagnosed pain [(back pain, chest
pain, osteo-/rheumatoid arthritis, hip pain, and sciatica, etc.) 16%],
anxiety (14%), and fatigue and malaise symptoms on 8% of the prescriptions. Neurologists frequently diagnosed chronic headache/migraine (34%), multiple sclerosis and Alzheimer’s disease (18%),
back, neck, and miscellaneous neuropathies [(diabetic peripheral
neuropathy, etc.) 15%] and Parkinson’s disease (6%), while prescribing largely SSRIs and tricyclic antidepressants (TCAs). Infectious disease specialists often diagnosed HIV and AIDS (63%) and
bipolar disorder (14%) in patients with off-label use prescriptions.
In terms of antidepressants, SSRIs and phenylpiperazine (eg trazodone, nefazodone) were the most commonly prescribed antidepressant classes. Pain specialists largely prescribed TCAs for neuropathic
back and neck pain and myofascial pain 97% of the time. OB/GYN
specialists most often diagnosed patients with urinary disorders
(20%), such as urinary frequency, dysuria, urge incontinence, and
urinary tract infections, while they prescribed TCAs and SSRI’s.
Gastroenterology and hepatology specialists often prescribed SSRIs
or phenylpiperazine in the setting of cirrhosis, chronic hepatitis C,

hepatic encephalopathy, irritable bowel syndrome (IBS), and diarrhea. Diagnoses related to weight, such as abnormal weight gain
and obesity, were matched with the majority of prescriptions being
issued by endocrinologists (66%), while miscellaneous antidepressants (eg bupropion) were issued in greatest proportion.

Sensitivity analysis
A sample of findings from the chart review of off-label use prescriptions is displayed in Table 4. Approximately 69% of the 270 prescriptions reviewed did not have a structured ICD-9/10 diagnosis
specifically associated with the medication in EHR. Of those that
did, the EHR-documented prescription diagnosis was often one or
all of the encounter diagnoses. Upon examining the free-text clinical
notes, however, it was found that 39% (n ¼ 105) of the random
sample of prescriptions included a physician-documented history of
depression as the primary reason for antidepressant therapy. For
prescriptions characterized as on-label, we found that our methodology using purely structured diagnosis data was 83% accurate in
identifying the physician-documented indication in free-text clinical
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Depressive disorders
Pain
Anxiety disorders
Symptoms
Digestive system disorders
Insomnia
Weight problems
Headache/migraine
Urinary system disorders
Dermatological conditions
Sleep disorders
Nicotine dependence
Fibromyalgia
Sexual dysfunction
Drug abuse
Bipolar
Alcohol abuse
Nausea and vomiting
Panic disorder
Abnormal vasomotor function—menopause
Pruritus
Eating disorders
Parkinson’s disease
Attention-deficit/hyperactivity disorder
Post-traumatic stress disorder
Premenstrual dysphoric disorder
Obsessive–compulsive disorder
Schizophrenia
Social phobia
Other

Number of
prescriptions (%)b
n ¼ 140 929 (100)

170 (8.8)

Abnormal vasomotor
function—menopause
Anxiety

Mood disorder, bipolar II disorder, bipolar mixed, bipolar depression, bipolar I, unspecified episodic mood disorder
Back pain, neuropathies, trigeminal neuralgia, osteoarthritis, limb pain, abdominal pain, joint
pains, etc.
Disc disorder, lumbar radiculopathy, low back pain, neck pain, neuropathic pain, cervical radiculopathy, thoracic or lumbosacral neuritis or radiculitis, facet arthropathy, postlaminectomy
syndrome, joint pain, cancer-related pain, limb pain, osteoarthritis, etc.
Urinary frequency, dysuria, urgency of urination, urge incontinence, nocturia, UTI, mixed incontinence, etc.
Menopause syndrome, symptomatic menopausal or female climacteric states, menopause, hot
flushes, menopausal symptoms, perimenopause, etc.
Anxiety, agoraphobia w/panic

HIV/AIDS

Diarrhea, constipation, IBS, dysphagia, abdominal bloating, chronic constipation, nausea, rectal
bleeding, gastritis, vomiting, Crohn’s disease, etc.
Coronary artery disease, atrial fibrillation, coronary atherosclerosis, CHF, mitral valve disorders,
chronic ischemic heart disease, aortic valve disorders, chronic diastolic heart failure, etc.
Headache, chronic migraine w/o aura, migraine w/o aura, migraine, chronic daily headache, tension headache, migraine w/ aura, daily persistent headaches, etc.
Multiple sclerosis, Alzheimer’s, dementia, other degenerative diseases of basal ganglia, frontotemporal lobar degeneration, etc.
Cervical radiculopathy, lumbar radiculopathy, neck pain, cervicalgia, neuropathic pain, neuralgias, back pain, brachial neuritis or radiculitis, diabetic neuropathy, etc.
Sleep disturbance unspecified, OSA, hypersomnia, RLS/PLM, narcolepsy, sleep apnea, delayed
sleep phase syndrome, REM sleep behavior disorder, etc.
Parkinson’s disease (paralysis agitans), secondary parkinsonism

Hypertension, essential hypertension, benign hypertension, elevated BP, hypertensive retinopathy
Back pain, knee pain, chest pain, neck pain, osteoarthritis, rheumatoid arthritis, shoulder pain,
abdominal pain, neuropathic pain, chronic pain, limb pain, sciatica, arthralgia, cervicalgia,
etc.
Hyperlipidemia, hypercholesterolemia, mixed hyperlipidemia, familial hyperlipidemia, other and
unspecified hyperlipidemia, etc.
Anxiety, generalized anxiety disorder, chronic anxiety, adjustment disorder, etc.
DM, T2DM, T2 or unspecified DM, diabetes uncomplicated adult-type II, T2DM controlled,
etc.
Fatigue, cough, other malaise and fatigue, memory loss, shortness of breath, dizziness, etc.

Prominent diagnosesc

(continued)

SSRI (87), Tricyclic

SSRI (63), Tricyclic

Tricyclic (90), SSRI

SSRI (43), Phenyl, Tricyclic,
Tetracyclic
Tricyclic (97)

SSRI (25), Tricyclic, Phenyl,
Tetracyclic, SNRI
SSRI (48), Tetracyclic, SNRI,
Tricyclic
SSRI (48), Phenyl, Tricyclic,
Tetracyclic
SSRI (66), Phenyl, Tetracyclic

SSRI (56), SNRI, Tricyclic,
Misc, Phenyl
Tricyclic (55), SNRI, SSRI

SSRI (64), Phenyl, Misc,
SNRI
SSRI (80), Misc, SNRI
SSRI (55), Phenyl, Tricyclic,
Misc, SNRI
SSRI (70), Phenyl, SNRI,
Misc
SSRI (62), Phenyl, Tricyclic,
Misc
SSRI (54), Phenyl, Tricyclic,
Misc
Tricyclic (76), SNRI, SSRI

SSRI (60), Phenyl, Misc, Tricyclic
SSRI (57), Phenyl, Tricyclic,
Misc

Drug class (%)c
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102 (5.3)

391 (20.3)

Urinary conditions

OB/GYN n ¼ 1923
(51.7)

148 (11.4)

Pain
2510 (92.3)

187 (14.4)

Bipolar

Pain

823 (63.3)

HIV

505 (6.2)

Parkinson’s Disease

Pain medicine/management n ¼ 2719 (52.5)

Infectious Disease n ¼
1300 (8.6)

524 (6.4)

Sleep disorders

1193 (14.6)

923 (4.4)

Cardiac conditions

Pain

1150 (5.5)

Digestive disorder

1459 (17.9)

1749 (8.4)

Symptoms

Cerebral degeneration

2962 (14.2)
1792 (8.6)

Anxiety
Diabetes

2787 (34.2)

3002 (14.4)

Hyperlipidemia

Headache/migraine

3231 (15.5)

Pain

Neurology n ¼ 8158
(42.3)

3296 (15.8)

Hypertension

Internal Medicine n ¼
20834 (26.7)

No. of off-label
Rx with Dx
class (%)b

Prominent diagnosis class

Specialty no. of off-label Rx (%)a

Table 3. Prescribing trends of antidepressant prescriptions for off-label uses by top 8 department specialties and diagnosis classes, 2010–2015
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Weight problems

Anxiety
Liver damage

Digestive disorder
Hepatitis
Pain

1438 (65.7)

197 (10.8)
180 (9.9)

1032 (56.6)
403 (22.1)
270 (14.8)

105 (5.9)
90 (5)
80 (4.5)

1205 (67.3)

No. of off-label
Rx with Dx
class (%)b
malignant neoplasm of breast (female), breast cancer, prostate cancer, malignant neoplasm of colon, colon cancer, lung cancer, malignant neoplasm of prostate, etc.
Nausea and vomiting, nausea alone, nonintractable vomiting w/nausea
Fatigue, cough, shortness of breath, weakness, debility
Neuropathies, abdominal pain, back pain, chest pain, cancer associated pain, trigeminal neuralgia, joint pains etc.
Diarrhea, IBS, constipation, abdominal bloating, colitis, regional enteritis, etc.
Chronic hepatitis C, hepatitis C w/o hepatic coma, hepatitis B
Abdominal pain, abdominal cramping, epigastric pain, leg pain, back pain, noncardiac chest
pain, chest pain, etc.
Anxiety, insomnia due to anxiety, acute reaction to stress, hypochondriasis
Cirrhosis w/o mention of EtOH, NASH, biliary cirrhosis, liver fibrosis, EtOH cirrhosis of liver,
hepatic encephalopathy, etc.
Abnormal weight gain, obesity unspecified, morbid obesity, overweight, excessive weight gain,
etc.

Prominent diagnosesc

Misc (89), SSRI

SSRI (54), SNRI
SSRI (70), Tricyclic, SNRI
SSRI (46), SNRI, Tricyclic,
Tetra
SSRI (60), Tricyclic, Misc
SSRI (70), Phenyl
SSRI (66), Tricyclic, Misc,
Tetracyclic
SSRI (89), Tricyclic
Phenyl (63), SSRI, Tetracyclic

SSRI (46), SNRI, Misc

Drug class (%)c
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Notes: Selective Serotonin Reuptake Inhibitor (SSRI) includes citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, and sertraline. Serotonin-Norepinephrine Reuptake Inhibitor (SNRI) includes desvenlafaxine,
duloxetine, levomilnacipran, and venlafaxine. Tricyclic antidepressants include amitriptyline, amoxapine, clomipramine, desipramine, doxepin, imipramine, nortriptyline, and protriptyline. Tetracyclic antidepressants include maprotiline and mirtazapine. Phenylpiperazine includes trazodone and nefazodone. Miscellaneous antidepressants include bupropion, vilazodone, and vortioxetine. Others include monoamine oxidase inhibitors
(MAOIs): phenelzine, tranylcypromine; Phenylpiperazine antidepressants: nefazodone, trazodone; and psychotherapeutic combinations: fluoxetine-olanzapine, amitriptyline-chlordiazepine, amitriptyline-perphenazine.
Abbreviations: Rx: prescription; Dx: diagnosis; Phenyl: phenylpiperazine; Misc.: miscellaneous; UTI: urinary tract infection; IBS: irritable bowel syndrome; EtOH: alcohol; NASH: nonalcoholic steatohepatitis; OSA: obstructive sleep apnea; RLS/PLM: restless legs syndrome/periodic limb movement; REM: rapid eye movement; BP: blood pressure; DM: diabetes mellitus; T2DM: type 2 diabetes mellitus; CHF: congestive heart failure.
aValues represent fraction of prescription totals by department: Internal Medicine, n ¼ 110721; Infectious Disease, n ¼ 20124; Neurology, n ¼ 19242; Pain Medicine/Management, n ¼ 6465; Gastroenterology & Hepatology, n ¼ 4333; OB/GYN, n ¼ 4452; Oncology, n ¼ 3807; Endocrinology, n ¼ 2583.
bNo. of prescriptions associated with each prominent diagnosis class are not mutually exclusive and will not necessarily sum to 100%.
cValues are listed in descending order, left to right, from most frequent to least frequent (Drug classes cover approximately 90% of drugs within the diagnosis class), while the % represent the most frequent drug class.
dOnly those cancers listed amongst the CMS Chronic Conditions Warehouse (CCW) were selected: breast, prostate, endometrial, lung, and colorectal.

Endocrinology n ¼
2189 (71.9)

Gastroenterology &
Hepatology n ¼
1822 (57.9)

Cancerd

Oncology n ¼ 1791
(50.3)

Nausea/vomiting
Symptoms
Pain

Prominent diagnosis class

Specialty no. of off-label Rx (%)a

Table 3. continued

240
JAMIA Open, 2018, Vol. 1, No. 2

Citalopram HBr 20 mg

Escitalopram Oxalate 5 mg

Citalopram HBr 20 mg

Escitalopram Oxalate 10 mg

Lung cancer, secondary malignant
neoplasm of retroperitoneum and
peritoneum, rash, malignant neoplasm of bronchus and lung
Breast cancer, malignant neoplasm
of breast
Dyssynergia, Gastroesophageal reflux disease, chronic constipation,
anxiety, and IBS
Insect bite, hepatitis C

Menopausal syndrome, nicotine addiction

Fluoxetine HCl 10 mg

Nortriptyline HCl 10 mg

Nortriptyline HCl 10 mg

Lumbar radiculopathy, disc disorder
of lumbar region, sacroiliitis,
spondylolisthesis grade 1, spinal
stenosis
Low back pain, disc disorder of lumbar region, lumbar radiculopathy,
knee pain, myofascial muscle pain,
foraminal stenosis of lumbar region
Vulvar pain, vulvitis

HIV, insomnia, PPD screen

Mirtazapine 7.5 mg

Nortriptyline HCl 25 mg

HIV, systolic murmur

Parkinson’s disease, localization-related epilepsy and epileptic syndromes, memory loss

Escitalopram Oxalate 5 mg

Nortriptyline HCl 25 mg

Headache, vertigo

Bupropion 75 mg

Hypercholesterolemia, HTN, spina
BIFIDA, T2DM, peripheral edema
Hypertension, smoking

Encounter diagnosis

Lung cancer

Vulvar pain, vulvitis

Insomnia

Parkinson’s disease, localization-related epilepsy
and epileptic syndromes, memory loss
HIV

Headache

Hypertension

Prescription diagnosis

Constipation (intermittent,
increased with anxiety)/
anxiety, worry

Mood

Symptoms of depression

Menopausal syndrome

HSV-associated pain

(continued)

“Pt was told to continue Lexapro. RX
options for her constipation were
reviewed”
“Very anxious about becoming depressed on
therapy. Extensive discussion. Given rx

“Citalopram for depressed mood”

“Pt is really bothered by the diagnosis (culture þ HSV1), told unlikely to recur. Start
nortriptyline and a local steroid”
“Menopausal syndrome—given smoking
and hyperlipidemia, we will try nonhormonal options. Rx prozac”
“Pt given for lexapro 10 mg daily  1 week
to be increased to 2 tabs (20 mg) daily for
sx’s of depression”

“Has been taking increased dose of nortriptyline since last visit and notes much less
pain radiating to leg”

Neuropathic pain

Neuropathic pain, Pt listed
as being depressed 4
months prior

“foot pain—chronic, not neuropathy apparently, will give trial of nortrip in case”
“still not entirely clear how pt is taking mirtazapine or how frequently. Advised that
pt try to take it every night, which may reduce overall anxiety”
“Back pain improved with addition of
nortriptyline”

“Depression: stable: continue Paxil and trazodone for sleep”
“history of migraines and depression, both
well controlled on bupropion and
amitriptyline”
“Will try an antidepressant to see if it helps
to improve interest in activities. The history is suggestive of depression”

“Insomnia—c/w trazodone at night”

Excerpt from clinical text

Chronic foot pain (not neuropathic)
OCD/insomnia, past Rx
also associated with
HIV, OCD

Depression

Depression and/or
migraines

Depression

Insomnia

Indication for prescription
in clinical text

Downloaded from https://academic.oup.com/jamiaopen/article-abstract/1/2/233/5106281 by University of South Carolina - Columbia user on 21 November 2019

Gastroenterology &
Hepatology

Oncology

OB/GYN

Pain Medicine/
Management

Infectious Disease

Neurology

Trazodone HCl 50 mg

Internal Medicine

Paroxetine 20 mg

Prescription

Specialty

Table 4. Sample of results from chart review of EHR-documented prescriptions for off-label uses (n ¼ 270)
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Clomipramine HCl 25 mg

Abbreviations: Rx: prescription; HTN: hypertension; T2DM: type 2 diabetes mellitus; HIV: human immunodeficiency virus; PPD: postpartum depression; OCD: obsessive–compulsive disorder; HSV: herpes simplex virus; Pt: patient.

Diabetes mellitus w/renal
complications

Weight loss, excessive
weight gain

“Discussed the use of bupropion for smoking and eating. Add bupropion 100 mg
SR in the morning/wellbutrin is helping
mood”
“bmi 37.5, discussed wt loss surgery and
drugs, on anafranil (Clomipramine)”
Bupropion HCl ER 100 mg
Endocrinology

Abnormal weight gain, essential hypertension, sleep disorder, proteinuria, impaired fasting glucose, and
mixed hyperlipidemia
Benign prostatic hyperplasia, DM w/
renal complications, HTN, lipids
abnormal, microalbuminuria,
Gastroesophageal reflux disease,
vitamin D deficiency, and Gout

Abnormal weight gain

Depression/anxiety associated with PEG-Intron
medication (Hep C)
Smoking cessation and excessive eating, and mood

Indication for prescription
in clinical text
Prescription diagnosis
Encounter diagnosis
Prescription
Specialty

Table 4. continued

notes. However, if we adjust for the patients with a reference to active depression in their notes—or multiple on-label indications during the same encounter—then our accuracy increased to 93%. On
average, the earliest diagnosis that could be considered on-label
was made 636 days (1.74 years) prior to the prescription date.

DISCUSSION
As the use of antidepressants rises in the US, partly due to a large
number of PCPs and nonpsychiatric specialists ordering these medications2,4—it has become increasingly important to understand the
prescribing patterns of nonpsychiatric specialties. The data mining
method employed in this study provided a unique probe to assess
“real-world” clinical data across a large number of prescriptions in
an outpatient setting. Further, it allowed us to examine the nuances
of provider documentation when interacting with the EHR’s CPOE
system, comparing structured diagnosis data to unstructured clinical notes.
By applying our method of matching antidepressant prescriptions
to prior diagnosis history, we were able to characterize antidepressant
prescriptions in the context of drug labels and evidence assessments
within the EHRs and CPOE at the institution. Our results suggest
that approximately 69% of the antidepressants issued through the
institution’s outpatient CPOE between 2010 and 2015 can be classified as an “on-label/evidence-based use.” Further, our methodology
allowed us to estimate the disease burden under which patients had
received antidepressants. Relying solely on coded (and structured) diagnosis data to infer prescription indications can be challenging, and
even inaccurate, as diagnosis codes are not always carried over to subsequent clinical encounters. Even though it may appear as though prescriptions are issued for off-label uses, there is often additional,
pertinent information that is captured throughout the EHR in unstructured clinical notes.34 Therefore, using only structured diagnosis
data to characterize prescription patterns could have led to false conclusions, and thus attempts to mine unstructured data throughout the
EHR should be considered for future studies. Additionally, nonpsychiatric clinicians have been shown to misdiagnose depression
based on uncertainty about the diagnosis and potential implications
based on the presence of the diagnosis code in EHRs.35–38 In accordance with this finding, recent studies have shown that clinical decision support mechanisms can be implemented directly into EHR
systems, which improve recognition and screening for conditions such
as postpartum depression and bipolar disorder.39,40 We attempted to
adjust for such complications by incorporating increasing medical history time frames—thereby accounting for physician changes and their
associated practice patterns, as well as collaborative and integrative
care. This analysis demonstrated that applying a 5-year time frame
allowed us to capture the correct indication with a relatively high degree of accuracy, although as discussed above, an on-label diagnosis
was identified, on average, 1.74 years prior to the prescription.
For prescriptions characterized as off-label use, structured diagnosis data alone were not enough to determine prescriptions indications. A sensitivity analysis revealed that a large proportion of
the patients had a physician-documented history of depression or
clinical note citing depression as the indication in unstructured clinical notes (39%), despite no formal ICD-9/10 code registered. This
finding may be partially explained by the fact that over half of the
off-label prescriptions lacked a formal association with a diagnosis.
Together, these results highlight a significant gap in recording
diagnoses of depression in the EHR using structured data and appear to give credence to claims that nonpsychiatric specialists may
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for celexa, aware not to initiate antidepressant treatment until we discuss first”

JAMIA Open, 2018, Vol. 1, No. 2

Excerpt from clinical text
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Significance and relation to current literature
To date, only a few studies have estimated disease burden and examined diagnosis-based prescribing patterns within the context of drug
labels and evidence assessments. To our knowledge, this is the first
study to have examined these patterns specifically for antidepressants prescribed to adults by nonpsychiatrists, through leveraging
outpatient EHR data from a large U.S. academic medical center. In
addition, we tried to control for potential overestimates of “off-label
uses” experienced by a previous study that used a short medical history window.19 Using a 5-year time frame revealed that the first onlabel diagnosis was made, on average, nearly 2 years prior to the
prescription in this population.
Our work followed a 2016 study from Wong et al.,20 which examined treatment indications in primary care practices for antidepressant
prescriptions in Quebec, Canada, and used approved product labels
dictated by the FDA and Health Canada as references.20 Wong et al.30
subsequently published a detailed study in 2017 in which they report
29% of approximately 106 000 prescriptions to be “off-label,” with
40% of those prescriptions having strong evidence of efficacy for another drug in the same class, but not the one prescribed. Their study
describes methods that are similar to those that we have used; however,
their data was collected via the Medical Office of the XXIst Century
(MOXXI), which is an EHR-based drug management and e-prescribe
system focused solely on PCPs in Canada, and required the documentation of specific indications when ordering medications.
There are three major differences between this study by Wong
et al. and our study. First, prescriptions were classified differently
according to evidence assessments. Second, our study examined the

prescribing trends across medical specialties, reaching beyond primary care. Third, we did not seek to determine within-class efficacy.
For our purposes, if the compendium registered a sufficient level
of evidence towards efficacy (benefit category I or IIa/b; evidence
category A or B), then we considered the medication as an “on-label/evidence-based use,” instead of “off-label.” While “on-label”
and “evidence-based” are distinct categories, they were conceptually
merged for most of the analyses because this clinical assumption represents a reasonable standard of care. Given this difference in prescription classification, we found a similar ratio of off-label
prescriptions (31%) as compared with Wong et al. (29%) amongst a
significantly larger sample size. Our analysis also extends beyond
primary care. We also examined patterns by the clinical department
of the prescriber—which had not been previously characterized. In
contrast to the strategies used by Wong et al. to assess within-class
efficacy, we attempted to estimate the conditions in which patients
were receiving these antidepressants (Table 3) and reviewed clinical
text to determine prescription indications (Table 4). This yielded a
significant number of prescriptions that should be reclassified as
“on-label/evidence-based use,” thus giving strength to current medical practice, and also demonstrated how nonpsychiatric specialists
may interact with the EHR/CPOE systems.

Study limitations
Our study has several limitations. Principally, our analysis is restricted by the structured data that is documented within the outpatient EHR. The EHR/CPOE allows prescribing clinicians the
opportunity to associate specific encounter diagnoses, all diagnoses,
or bypass associations entirely when ordering medications. Thus,
documenting an associated indication is not a necessary step for ordering prescriptions. The only method of retrospectively assessing a
physician’s order would be to examine all EHR-documented prescriptions individually or work with hospital information technology services to tailor data retrieval. Since the study relied on
examining medication–diagnosis pairs, some prescriptions were lost
due to lack of a documented diagnosis. In addition, the subjective
nature of clinical diagnostics influences prescribing patterns, thus
studying the ICD-9/10 diagnosis data alone does not provide sufficient insight into the rationale behind practice patterns. While a sensitivity analysis was conducted on 1% random samples of patients
receiving on-label and off-label use prescriptions, review of all
35 325 charts would have required automated NLP—which is out
of scope for this article. For on-label use prescriptions, these were estimated based on prior medical history and subsequent verification,
whereas off-label use prescriptions required a manual chart review
and extrapolation of results. Therefore, we do not have a comprehensive view of diagnosis and antidepressant prescribing trends, and
definitive conclusions about the overall percentage of prescriptions
written for off-label uses cannot be drawn from the existing data.
Our results are also based on the DrugDex System reports as of
August 2016. Any updates to drug evidence, or the addition of
newer drugs to the market during the study period, almost certainly
will have had an influence on prescription patterns. However,
attempting to analyze these temporal factors in the study would
have complicated interpretation of results, therefore we applied the
latest product labels and strength of evidence to each of the antidepressants represented. Using this approach, Figure 3 demonstrates
that the number of prescriptions classified as “evidence-based use”
nearly plateaus after 1 year of medical history inclusion, while the
number of on-label and off-label use prescriptions continue to increase
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be hesitant to formally diagnose depression.35–38 We see this trend
within neurology and internal medicine specialty notes, as nearly
half of all prescriptions examined showed either active or history of
depression that was not documented in the form of a structured data
entry using ICD-9/10 diagnosis codes. This study however was not
limited to depression, as anxiety (25%), insomnia (13%), mood disorder (7%), and neuropathic pain (5%) were all cited as a reason
for antidepressant therapy in progress notes but lacked ICD-9/10
codes in diagnosis history. These findings also suggest that secondary use of EHR data could be improved by requiring physicians to
document a diagnosis code when issuing prescriptions through the
CPOE, particularly in the absence of advanced natural language
processing (NLP) techniques.
The chart review further revealed that the number of prescriptions without sufficient evidence to support their efficacy may be
even lower. We found that 92% of the off-label use prescriptions examined within pain medicine/management specialty notes were, in
fact, nortriptyline or duloxetine for the treatment of neuropathic
pain. Despite exclusion from the drug reference compendium, there
have been a number of well-discussed and rigorous studies that support the use of TCAs and serotonin-norepinephrine reuptake inhibitors (SNRIs) when treating neuropathic pain.41–46 These drugs may
have a weaker evidence base, but they display some potential to alleviate suffering and pose less severe risks than alternatives. The
American College of Physicians, for example, recently published
new guidelines for the treatment of low back pain—often characterized by neuropathies—which emphasize nondrug therapies, but suggest that an antidepressant such as duloxetine (SNRI) may be
appropriate if pain persists.47,48 These results imply that prescribing
for off-label uses—or prescribing without sufficient evidence of efficacy, may occur less frequently than believed.23,30
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CONCLUSIONS
The results indicate that antidepressants may be prescribed for offlabel uses, by PCPs and nonpsychiatry specialists, less frequently
than believed. This study also points to the fact that there are a number of off-label uses that are efficacious and widely accepted by expert clinical opinion, but have not been included in drug compendia.
Despite the fact that diagnosis codes in the outpatient setting are notoriously inaccurate, our approach demonstrates that the correct
codes are often documented at some point in a patient’s recent diagnosis history. Because such a wide range of medical specialties are
using antidepressants, there is benefit in studying routinely collected
data in EHRs. That is, to better understand the prescribing patterns
of providers outside of controlled research settings, in which study
participants tend to be homogeneous.
However, depending on the EHR system, structured diagnosis/
billing data alone may be insufficient to track indications and carry
out prescription classification. Instead, a more robust methodology
for future EHR-based studies should include an analysis of unstructured clinical text using NLP, in addition to structured diagnosis
data. Examining these data elements in conjunction will help to triangulate and validate findings, thereby producing more accurate
and meaningful results. While our results confirm several patterns
reported by previous studies, the data are not comprehensive and
larger studies across several health systems will be required to draw
significant conclusions. Finally, the results also highlight some of the
challenges of secondary use of EHR data.
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